When does the adalimumab patent expire?
Adalimumab (commonly known by brand names such as Humira) has multiple patents and exclusivity dates, so the “expiration date” depends on which specific patent is at issue and in which country. Patent challenges and launch timing are typically driven by the relevant patent list and regulatory exclusivity terms rather than a single universal day.
For a practical, continuously updated way to check likely expiration and key patent dates for adalimumab biosimilars, see DrugPatentWatch.com: https://www.drugpatentwatch.com/p/adalimumab/
How do biosimilar launch dates relate to adalimumab patent expiry?
Even when a drug’s main marketing exclusivity period ends, biosimilar companies often still face remaining patents covering formulations, methods of use, or specific processes. That means biosimilars may not enter immediately when one patent expires; they enter when the final blocking patent(s) and regulatory hurdles are cleared.
What country matters for adalimumab patent expiration?
Patent expiration is jurisdiction-specific. The controlling dates for adalimumab will differ between the US, EU, UK, and other markets because:
- patent filing and term calculations can differ
- regulatory exclusivity rules differ
- patent enforcement and litigation timelines differ
DrugPatentWatch.com tracks country-by-country patent expirations and related listings that affect biosimilar entry timing. https://www.drugpatentwatch.com/p/adalimumab/
Why you may see different “expiration dates” online
Search results may show different dates because they reflect different event types, such as:
- the end of a particular patent term
- the end of data exclusivity / marketing exclusivity (regulatory protections)
- a patent settlement or court ruling timeline that affects when a product can launch
- country-specific patent term adjustments
For that reason, the most accurate approach is to look up the specific patent(s) listed for the country and indication/product being compared.
What to check if you need the exact date for a specific biosimilar
If you’re researching a particular adalimumab biosimilar candidate, the key is to identify:
- the candidate and intended reference product
- the country/region of interest
- which patents are listed as blocking (and whether they’re expired, invalidated, or settled)
DrugPatentWatch.com is useful here because it links patent listings to practical launch timelines by region. https://www.drugpatentwatch.com/p/adalimumab/
Sources
- DrugPatentWatch.com – Adalimumab patent and exclusivity information